Andira Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Andira Pharmaceuticals is advancing novel therapeutics in infection control and oncology. The company is currently seeking Series A financing and strategic development partnerships.
Silvanex is a novel silver-based antimicrobial agent with 8x increased potency, featuring a novel synergistic mechanism of action, dual bactericidal and fungicidal activity, while utilizing a lower silver concentration. Silvanex rapidly eliminates antimicrobial resistant (AMR) pathogens and prevents new resistance.
Andira is advancing Silvanex Topical (drug candidate) for the prevention of surgical site infection, where no topical antimicrobials are currently approved.
In parallel, Andira is developing a first-in-class oncology platform using localized, transdermal delivery of dronabinol (synthetic Δ9-THC). This non-psychotropic, targeted approach is being applied to Stage 0 breast cancer (DCIS) and post-mastectomy pain. Both programs are eligible for 505(b)(2) FDA clearance.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}